Peri-Implantitis
Conditions
Keywords
Peri-Implantitis, Dental Implants, Hyaluronic Acid, Clinical Trial
Brief summary
The effect of the hyaluronic acid treatment on peri-implantitis has not been tested. The aim was to analyze the effect of a hyaluronic acid-containing gel on the clinical variables and the expression of biochemical inflammatory markers in the crevicular fluid of implants receiving perimplantitis treatment.
Detailed description
The aim was to analyze the effect of a hyaluronic acid-containing gel on the clinical variables and the expression of biochemical inflammatory markers in the crevicular fluid of implants receiving perimplantitis treatment. A randomized, controlled, double-blind clinical trial was designed on 100 perimplantitis affected implants placed in 61 subjects. Inclusion criteria were implants with at least 1 year of functional loading and with diagnosis of perimplantitis following the criteria from the Association of Dental Implantology. All implant received perimplantitis treatment. Each patient was randomly assigned to receive a gel containing 0.8% HA (Test group), a gel without HA (Placebo group) or no gel treatment (Control group). After a first gel application at baseline, test and placebo patients performed gel applications at home 3 times/day for 45 days. Clinical variables of each implant were recorded at baseline, 45 and 90 days (probing depth, attachment loss, bleeding). Intraoral radiographs of each implants were performed to measure marginal bone level. Peri-implant crevicular fluid was collected from each implant at baseline and after 45 days of treatment, to assess IL-1β and TNFα levels by ELISA technique. Clustering analysis, considering multiple implants within each patient, was performed.
Interventions
DRUGHyaluronic Acid
Hyaluronic acid gel application as coadjuvant in the treatment of perimplantitis.
DRUGHydroxypropyl Guar
Hydroxypropyl Guar gel application as sham comparator
Sponsors
Ricerfarma S.r.l
Universidad de Granada
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Implants with at least one year of functional load. * Implants diagnosed with peri-implantitis according to the criteria of the Association of Dental Implantology.
Exclusion criteria
* Previous peri-implantitis treatment. * Pregnancy or breast-feeding. * Neoplastic disease. * Antibiotic treatment during the previous month.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Peri-implant probing depth | Baseline, change at 45 days and at 90 days. | Probing depth (mm) assessed by periodontal probe. |
| Peri-implant attachment level | Baseline, change at 45 days and at 90 days. | Probing attachment level (mm) calculated using probing depth and exposed implant threads. |
| Peri-implant bleeding | Baseline, change at 45 days and at 90 days. | Bleeding on probing expressed as % of bleeding implants in each group. |
| Marginal Bone level | Baseline, change at 45 days and at 90 days. | Alveolar bone level assesed in periapical digital radiographs by image processing software (ImageJ). |
| Peri-implant crevicular fluid cytokines. | Baseline and change at 45 days. | Inflammatory cytokines (IL1B and TNFa) measured in Peri-implant crevicular fluid by ELISA. |
Outcome results
None listed